What does an elevated DHEA (dehydroepiandrosterone) level of 377 µg/dL indicate in a female and how should it be evaluated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Elevated DHEA Level of 377 µg/dL in a Female

An elevated DHEA level of 377 µg/dL in a female is moderately elevated but does not reach the critical threshold of 600 µg/dL that would indicate an adrenal tumor requiring urgent imaging. This level most commonly suggests polycystic ovary syndrome (PCOS) with adrenal androgen excess, though other causes must be systematically excluded 1.

Clinical Significance and Interpretation

DHEA (dehydroepiandrosterone) and its sulfate form DHEAS are primarily produced by the adrenal cortex and serve as markers of adrenal androgen production. A level of 377 µg/dL falls into the moderately elevated range:

  • Critical threshold: DHEAS >600 µg/dL suggests adrenal cortical adenoma (often with hypercorticism) and mandates urgent abdominal CT or MRI 1
  • Your patient's level (377 µg/dL): Indicates adrenal androgen excess but below the tumor threshold

Approximately 20-30% of PCOS women demonstrate excess adrenal androgen production, and elevated DHEAS is found in 60% of hirsute women 2, 3. Importantly, 77% of women with elevated DHEAS are non-hirsute, so absence of hirsutism does not exclude hyperandrogenism 4.

Systematic Evaluation Algorithm

Step 1: Measure Complementary Androgens

Check early morning (before 10 AM) total testosterone and free testosterone 5:

  • If testosterone is >2× upper limit of normal, this increases concern for ovarian hyperthecosis or androgen-secreting ovarian tumor
  • DHEAS elevation combined with testosterone elevation suggests generalized hyperandrogenism rather than isolated adrenal excess 1

Step 2: Exclude Life-Threatening Causes

Even at this moderate DHEAS level, systematically rule out:

  • Pregnancy test if amenorrheic
  • Pelvic ultrasonography to detect ovarian neoplasm or polycystic ovaries
  • 17-hydroxyprogesterone (early morning, follicular phase) if high-risk ethnicity (Ashkenazi Jewish, Hispanic, Slavic) or family history suggests congenital adrenal hyperplasia 5
  • Prolactin level to exclude hyperprolactinemia
  • Clinical assessment for Cushing's syndrome (central obesity, striae, moon facies), thyroid dysfunction, or acromegaly if suggestive features present 5

Step 3: Assess for PCOS

Look for the following features that increase likelihood of PCOS 5:

  • Menstrual irregularity or anovulation
  • Clinical hyperandrogenism (hirsutism, acne, seborrhea, androgenic alopecia)
  • Central obesity
  • Acanthosis nigricans
  • Family history of type 2 diabetes
  • Insulin resistance markers

PCOS is the most common cause of this presentation, accounting for the majority of moderate DHEAS elevations in reproductive-age women 2.

Step 4: Consider Medication History

Obtain detailed medication history:

  • Valproic acid is the only anticonvulsant that raises testosterone levels 5
  • Androgenic medications (anabolic steroids, danazol)
  • Medications with estrogenic effects that alter SHBG (certain antiepileptics)

Additional Diagnostic Considerations

If initial workup is negative but clinical suspicion remains high:

  • Androstenedione levels may provide additional information 1
  • SHBG measurement helps interpret total testosterone (typically reduced in obesity, metabolic syndrome) 1
  • Dexamethasone suppression testing can help differentiate adrenal from ovarian sources 1, 6
  • ACTH stimulation test may reveal exaggerated adrenal response (34% of patients with elevated DHEAS show this pattern) 4

Important Caveats

Age matters significantly: DHEAS values decline by approximately 40% from the twenties to thirties, so interpretation must be age-adjusted 7. Younger women (20-29 years) with PCOS show higher prevalence of elevated DHEAS, particularly in non-classic PCOS phenotypes (B and C) 7.

Timing of testing: Measure androgens in early morning during follicular phase (days 4-10) in regularly cycling women, as this is when norms are standardized 1, 5.

Common pitfall: Do not assume normal testosterone excludes significant pathology. Some women have isolated DHEAS elevation, and approximately 7.7% have elevated DHEA with normal testosterone 6.

Clinical Implications for Morbidity and Mortality

While this DHEAS level doesn't suggest immediate life-threatening pathology, failure to diagnose underlying PCOS carries significant long-term risks including:

  • Type 2 diabetes mellitus
  • Cardiovascular disease
  • Endometrial hyperplasia/cancer (from chronic anovulation)
  • Infertility

Paradoxically, elevated DHEAS may be protective against cardiovascular risk in the general population, though this relationship in PCOS remains unclear 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.